Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Tuesday. They currently have a $75.00 price target on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 35.01% from the company’s previous close.

SRPT has been the topic of a number of other reports. Credit Suisse Group reiterated an “outperform” rating and issued a $81.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Robert W. Baird reiterated a “buy” rating and issued a $101.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, October 17th. Oppenheimer reiterated a “buy” rating and issued a $76.00 price objective on shares of Sarepta Therapeutics in a report on Wednesday, December 27th. William Blair reiterated an “outperform” rating on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Finally, JPMorgan Chase & Co. restated a “hold” rating on shares of Sarepta Therapeutics in a research note on Monday, September 25th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and seventeen have given a buy rating to the company’s stock. Sarepta Therapeutics currently has a consensus rating of “Buy” and an average target price of $63.88.

Sarepta Therapeutics (NASDAQ:SRPT) traded up $1.53 on Tuesday, reaching $55.55. The company had a trading volume of 1,026,157 shares, compared to its average volume of 2,629,540. Sarepta Therapeutics has a 12-month low of $26.26 and a 12-month high of $59.95. The firm has a market capitalization of $3,600.00, a PE ratio of -27.23 and a beta of 1.37. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.66. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. The firm had revenue of $45.95 million for the quarter, compared to analysts’ expectations of $41.29 million. During the same period in the prior year, the firm posted ($0.95) earnings per share. equities analysts predict that Sarepta Therapeutics will post -3.07 earnings per share for the current year.

In related news, CEO Douglas S. Ingram acquired 38,138 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, November 8th. The shares were acquired at an average cost of $52.44 per share, for a total transaction of $1,999,956.72. Following the completion of the purchase, the chief executive officer now owns 420,196 shares in the company, valued at $22,035,078.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the completion of the sale, the director now owns 13,333 shares in the company, valued at $745,181.37. The disclosure for this sale can be found here. 9.60% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Neuberger Berman Group LLC acquired a new stake in shares of Sarepta Therapeutics in the third quarter valued at $1,134,000. California Public Employees Retirement System increased its holdings in Sarepta Therapeutics by 1.2% in the third quarter. California Public Employees Retirement System now owns 142,900 shares of the biotechnology company’s stock valued at $6,482,000 after buying an additional 1,700 shares during the last quarter. Janney Montgomery Scott LLC purchased a new position in Sarepta Therapeutics in the third quarter valued at $474,000. Ladenburg Thalmann Financial Services Inc. increased its holdings in Sarepta Therapeutics by 140.9% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 2,493 shares during the last quarter. Finally, Highbridge Capital Management LLC purchased a new position in Sarepta Therapeutics in the third quarter valued at $922,000. Institutional investors and hedge funds own 82.02% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/09/sarepta-therapeutics-srpt-buy-rating-reiterated-at-hc-wainwright.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.